期刊文献+

超滤法纯化C群脑膜炎球菌荚膜多糖降解物的工艺优化 被引量:2

Optimization of purification procedure for capsular polysaccharide hydrolyzate of Neisseria meningitidis group C by ultrafiltration
原文传递
导出
摘要 目的优化超滤法纯化C群脑膜炎球菌荚膜多糖降解物的工艺。方法以截留分子量为300 000的超滤膜对C群脑膜炎球菌荚膜多糖降解物进行超滤分离,以膜通量和多糖回收率为评价指标,优化方法中的超滤膜材质(300 k Da的聚醚砜膜和再生纤维素复合膜)、透析次数(1~6次)、超滤缓冲液(0.15 mol/L Na Cl、0.5 mol/L Na Cl、50 mmol/L的PBS和H2O)、多糖初始溶解浓度(0.25、0.5和1 mg/m L)和超滤方式(浓缩补液超滤和恒体积超滤)。采用最佳条件对C群脑膜炎球菌荚膜多糖降解物进行检测。结果 C群脑膜炎球菌荚膜多糖降解物的最佳超滤条件为:以再生纤维素复合膜为超滤膜,0.15 mol/L Na Cl为超滤缓冲液,透析次数为5次,多糖初始溶解浓度为1.0 mg/m L,超滤方式为浓缩超滤。该方法可有效去除C群脑膜炎球菌荚膜多糖降解物中较大分子量的多糖组分,多糖回收率在80%以上,且可在一定程度上降低多糖水解物的内毒素含量。结论成功优化了超滤法纯化C群脑膜炎球菌荚膜多糖降解物的工艺,显著提高了工作效率。 Objective To optimize the purification process for capsular polysaccharide hydrolyzate of Neisseria meningitidis group C by ultrafiltration. Methods The capsular polysaccharide hydrolyzate of N. meningitidis group C was purified by ultrafiltration using the ultrafiltration membrane with relative molecular mass cutoff of 300 000. The ultrafiltration membrane material(300 k Da polyethersulfone membrane and regenerated cellulose composite membrane),times of dialysis(1 - 6),ultrafiltration buffer(0. 15 mol/L sodium chloride,0. 5 mol/L sodium chloride,50 mmol/L PBS and water),initial liquid concentration of polysaccharide(0. 25,0. 5 and 1 mg/m L) and ultrafiltration method(concentrated ultrafiltration and constant volume ultrafiltration)were optimized using membrane flux and polysaccharide recovery rate as evaluation indexes. The hydrolyzate purified under the optimal condition was tested. Results The optimal ultrafiltration membrane, ultrafiltration buffer, time of dialysis, initial liquid concentration of polysaccharide and ultrafiltration method for hydrolyzate of capsular polysaccharides of N. meningitidis group C were regenerated cellulose composite membrane,0. 15 mol/L sodium chloride,5 times,1. 0 mg/m L and concentrated ultrafiltration respectively.Under this condition,the polysaccharide components with high relative molecular masses were effectively removed,while the polysaccharide recovery rate was more than 80%,and the polysaccharide hydrolyzate endotoxin content decreased to a certain extent. Conclusion The purification procedure for capsular polysaccharide hydrolyzate of N. meningitidis group C was successfully optimized,which significantly improved the working efficiency.
作者 周晖国 张海红 袁菲 罗树权 李阿妮 应莲芳 ZHOU Hui-guo;ZHANG Hai-hong;YUAN Fei;LUO Shu-quan;LI A-ni;YING Lian-fang(Lanzhou Institute of Biological Products Co.,Ltd.,Lanzhou 730046,Gansu Province,China)
出处 《中国生物制品学杂志》 CAS CSCD 2018年第8期896-901,共6页 Chinese Journal of Biologicals
关键词 超滤 C群脑膜炎球菌 荚膜多糖 降解物 工艺优化 Ultrafiltration Neisseria meningitidis group C Capsular polysaccharide Hydrolyzate Procedure optimization
  • 相关文献

参考文献1

二级参考文献10

  • 1World Health Organization.Guidelines on transfer of technology in pharmaceutical manufacturing[S].WHO Technical Report Series,2011,762:115-158.
  • 2Berti F,Romano MR,Micoli F,et al.Relative stability of meningococcal serogroup A and X polysaccharides[J].Vaccine,2012,30(45):6409-6415.
  • 3Micoli F,Romano MR,Tontini M,et al.Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X[J].Proc Natl Acad Sci USA,2013,110(47):19077-19082.
  • 4Cook MC,Gibeault S,Filippenko V,et al.Serogroup quantitation of multivalent polysaccharide and polysaccharide-conjugate meningococcal vaccines from China[J].Biologicals,2013,41(4):261-268.
  • 5Ilyina N,Kharit S,Namazova-Baranova L,et al.Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children,adolescents and adults in Russia[J].Hum Vaccin Immunother,2014,10(8):2471-2481.
  • 6The European Pharmacopoia Department.European Pharmacopoeia 7.0[S].3rd ed.Strasbourg:European Directorate for Quality Medicines,1997:1155-1157.
  • 7Lemercinier X,Jones C.Full1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production[J].Carbohydr Res,1996,296(1):83-96.
  • 8Lindon JC,Vinter JC,Lifely MR,et al.Conformational and dynamic differences between N.meningitidis serogroup B and C polysaccharides,using n.m.r.spectroscopy and molecular mechanics calculations[J].Carbohydr Res,1984,133(1):59-74.
  • 9Jones C,Lemercinier X.Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture[J].J Pharm Biomed Anal,2002,30(4):1233-1247.
  • 10李阿妮,于旭博,罗树权,胡浩,吴兵,赵志强,谢贵林.A群脑膜炎球菌荚膜多糖化学结构核磁共振检测方法的建立[J].中国新药杂志,2013,22(23):2751-2758. 被引量:4

共引文献4

同被引文献25

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部